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Autologous tumor cell-based vaccines (ATCVs) have a
number of potential advantages including multivalency
and patient specificity. ATCVs contain many potential
antigens, both known and unknown which potentiate
polyclonal responses capable of responding to a more
diverse population of tumor cells. In addition, because
ATCVs are created from a patient’s own tumor, all poten-
tial immunogenic epitopes are patient specific and each
patient is immunized against her complete and individua-
lized antigen repertoire. This is particularly important for
breast cancer as each tumor can contain up to 100 differ-
ent mutant genes so no two tumors are identical.
The major disadvantage of ATCVs, is poor immuno-
genicity. In order to develop an effective, immunogenic
ATCV against breast cancer, we wanted to understand the
features of immunogenicity. In this study, BALB/c female
mice were given priming and booster vaccinations, ten
days apart, with 1 million irradiated (100Gy) EMT6 and/
or 4T1cells. Ten days after the booster vaccination, mice
were challenged with live tumor cells. 80% of mice vacci-
nated with EMT6 cells were completely protected against
a live EMT6 challenge. However, mice vaccinated with
irradiated 4T1 cells failed to provide any protection against
a live 4T1 challenge. Most interestingly, when mice were
vaccinated with a mixture of irradiated EMT6 and 4T1
cells at the same site, the protective response against
EMT6 challenge was significantly diminished as 60% of
mice developed tumors. Furthermore, when irradiated
EMT6 and 4T1 cells were administered on opposite sides,
protection from an EMT6 challenge was also significantly
diminished with 88% of mice developing tumors. This
finding implied that non-immunogenic irradiated 4T1
cells released one or more immunosuppressive factors that
inhibited anti-EMT6 immunity.
Thus, we investigated the levels of different immunosup-
pressive cytokines, G-CSF, M-CSF, GM-CSF, IL-6, MCP-
1, TGF-b and VEGF released by both 4T1 and EMT6 cells
before and after irradiation. Irradiated 4T1 cells secreted
high levels of colony stimulating factors. Specifically, at 24
and 48 hours after irradiation, 4T1 cells secreted 60 and
705 pg/ml of M-CSF; 912 and 5190 pg/ml of G-CSF; 29
and 180 pg/ml of GM-CSF. We believe that high levels of
colony stimulating factors induce the accumulation of
large amounts of myeloid derived suppressor cells
(MDSCs) in the tumor site and lymphoid organs which, in
turn, suppress anti-EMT-6 immunity. Future studies will
determine if blocking colony stimulating factors will
decrease the accumulation of MDSCs and subsequently
increase anti-tumor immunity.
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